BioSpectrum the business of Bio & Health Sciences ASIA EDITION

CF PharmTech to accelerate respiratory drugs development

January 2, 2020 | News

Raised a $90 million Series E investment led by New Alliance Capital

China based CF PharmTech, Inc., a pharmaceutical company with a vision to provide quality and affordable respiratory drug products globally, announced it has raised a $90 million Series E investment led by New Alliance Capital.

The investment included participation from new investors CR-CP Life Science Fund, Finnova Capital, GT Capital, Co-stone Asset Management, Xiangcheng Financial Holdings, Everest Venture Capital, and existing investors, such as Oriza Holdings, Longmen Venture Capital, GTJA Investment and CMB International.

The completion of this round of funding reflects the strong support from China's investors to fuel high-caliber pharmaceutical companies that have a strong global competitive edge, and will allow CF PharmTech to bring products in its pipeline to market.

With respect to this round of financing, New Alliance Capital Executive Director Lei Cai explained: "New Alliance Capital prioritizes investment opportunities in the healthcare industries. Respiratory treatments and inhaled medications, in particular, are promising because of the high technological barriers to entry and immense potential for growth. CF PharmTech has worked meticulously to build strong technological platforms that support the development of a comprehensive range of products. The integrity and professionalism of the core team at CF PharmTech impressed us deeply."